Lobbying registration dated 2026-01-23
Registrant: Philip Delistoyanov
Client: Alexion Pharma Canada Corp.
Targeted institutions:
Finance Canada (FIN)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Acts: Food and Drugs Act
Government funding received:
Lobbying activity details:
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.